Australia’s prothrombin complex concentrate (PCC), PROTHROMBINEX-VF, will be changing in 2024 as one of five domestic plasma product transitions taking place across 2023 and 2024. More information on these transitions can be found here: Transition of Australia's domestic plasma products.
It is anticipated PROTHROMBINEX-VF will be available until around June 2024. To ensure there is continued access to human PCC between that time and when the domestic replacement BERIPLEX AU will become available in late 2024/early 2025, a short-term supply of BERIPLEX P/N (an imported product manufactured with plasma collected overseas) will take place.
BERIPLEX P/N and BERIPLEX AU are both four-factor PCCs containing human coagulation factors II, VII, IX, and X. More information about the initial transition from PROTHROMBINEX-VF to BERIPLEX P/N, including product information, timing and implementation will be released in early 2024 to relevant stakeholders.
Please direct any queries to the National Blood Authority at Supply.Management.Plasma@blood.gov.au or 13 000 BLOOD (13 000 25663).
Print